There is limited data available on the efficacy and safety of Transscleral Lutein Iontophoresis (TSLI) in patients with in-termediate age-related macular degeneration (iAMD) and reticular pseudodrusen (RPD).

This retrospective multicentre study evaluated the functional and morphological outcomes of TSLI in patients with stage 2 and stage 3 iAMD with RPD. Autofluorescence (AF), Optical Coherence Tomography (OCT), Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP), Macular Sensitivity (MS) and adverse events, were recorded at baseline, 1 month and 3 months follow-up after treatment.

Inclusion criteria

• Age between 55 and 80 years old
• diagnosis of early to intermediate stage dAMD (based on AREDS criteria)
• presence of RPD
• Treated with scleral Lutein Iontophoresis

Exclusion Criteria:

• GA or MNV in the included eye
• any prior or any ongoing medical or surgical treatment of the included eye (including intravitreal injections, oral supplementation of lutein, zeaxanthin and or high dietary intake of antioxidants)
• smokers (consummation of more than 20 cigarettes per day)
• history of treatment with drugs with a well-known possible ophthalmic side-effect
• known eye diseases such glaucoma, acute or chronic uveitis, advanced cataract, stage 4 dry eye disease or any opacities of the ocular media that do not permit high-quality imaging examinations
• manifest refraction outside of -6 and +4 dioptres
• BCVA < 40 EDTRS letters.

Patients from the regions of Naples and Cagliari